Removal of DATA Waiver (X-Waiver) Requirement

SAMHSA

Section 1262 of the Consolidated Appropriations Act, 2023 (also known as Omnibus bill), removes the federal requirement for practitioners to submit a Notice of Intent (have a waiver) to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). With this provision, and effective immediately, SAMHSA will no longer be accepting NOIs (waiver applications).

American Medical Association Releases Overdose Toolkit

American Medical Association

The American Medical Association has released a toolkits that recommends states expand treatment of opioid use disorder in Medicaid and commercial insurance and remove barriers, such as prior authorization and other utilization management policies. Additionally, treatment must address disparities and the needs of all patients equitably, including vulnerable populations. The toolkit also highlights the importance […]

Thank you for your patience while we make improvements

Meeting between healthcare professionals

PCSS is in the midst of updating its learner management system with the goal of making your life easier. While we do this, we’re encountering a few bumps in the road. Ultimately, we hope your learning experience is more seamless while we continue to offer webinars, clinical round tables, and all the other trainings you’ve […]

DEA Issues Urgent Message About Lethal Fake Prescription Drugs

Drug Enforcement Administration, Department of Justice

WASHINGTON, DC –Today, the Drug Enforcement Administration issued a Public Safety Alert warning Americans of the alarming increase in the lethality and availability of fake prescription pills containing fentanyl and methamphetamine. DEA’s Public Safety Alert, the first in six years, seeks to raise public awareness of a significant nationwide surge in counterfeit pills that are […]